Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Introduction of new tariffs for rapid diagnostics performed in pharmacies in France

With the Order of June 17, 2024, France introduced tariffs for rapid diagnostic tests performed by pharmacists. The new tariffs were set at €10 for rapid diagnostic tests without subsequent medication dispensation and €15 for tests that lead to immediate drug dispensation without a prescription. Under the current public health code, pharmacists can administer rapid diagnostic tests for Group A Streptococcal pharyngitis and urinary tract infections. A separate order specified the patient’s pathways and the service’s terms and conditions.

The full details in French can be found here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.